Published • loading... • Updated
Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss
Plaintiffs allege the companies failed to warn that the drugs may cause NAION, a rare eye condition that can lead to blindness.
- Thousands of lawsuits, including at least 4,000 consolidated complaints, target Eli Lilly and Novo Nordisk, alleging the drugmakers failed to warn patients of NAION, an "eye stroke" causing permanent vision loss linked to popular GLP-1 medications.
- NAION, often called an "eye stroke," is a rare condition causing sudden vision loss; while some studies suggest an association with GLP-1s, researchers have not established a definitive cause-and-effect relationship, and the disorder is more common in people over 50.
- Novo Nordisk updated European labels to note a risk of 1 in 10,000 patients, but the FDA maintains no such requirement in the U.S., while both Novo Nordisk and Eli Lilly deny any significant relationship between their drugs and NAION.
- Complaining parties allege that Eli and Novo "failed to communicate" increased risks, with one Pennsylvania lawsuit claiming defendants concealed risks to create the impression these medications were "magic pills" to help a person lose weight.
- Litigation continues as patients seek damages for complications including gastrointestinal injury; current research remains mixed, as a 2024 study of nearly 17,000 people failed to establish causation, leaving medical consensus on drug safety uncertain.
Insights by Ground AI
Podcasts & Opinions
7 Articles
7 Articles
Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss
Hundreds of consumers are suing makers of GLP-1 drugs like Ozempic and Wegovy, alleging semaglutide medications may increase the risk of NAION, a rare eye stroke causing vision loss.
·New York, United States
Read Full Article
Coverage Details
Total News Sources7
Leaning Left4Leaning Right2Center1Last UpdatedBias Distribution57% Left
Bias Distribution
- 57% of the sources lean Left
57% Left
L 57%
14%
R 29%
Factuality
To view factuality data please Upgrade to Premium
